Key Facts GPs Should Know About GLP-1 Analogs
Family Medicine Initiative
APRIL 9, 2024
In March 2024, FDA therefore approved semaglutide for secondary CVD prevention in overweight or obese adults. 5 In March 2024, Novo Nordisk announced that 24% less CKD-related events occurred in the intervention group. Relative risk for cardiovascular events was reduced by 19% (RRR), while the absolute risk was reduced by 1.5%
Let's personalize your content